Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Effect and risk factor of adverse drug events in using dapaglilfozin with type 2 diabetes mellitus patients.

  • In: Poster presentation
  • At: Seoul (South Korea) (2017)
  • Type: Poster
  • Poster code: POS-HPS-068
  • By: KIM, Kwi (Seoul National University Hospital, Pharmacy, Seoul, Korea, Republic Of)
  • Co-author(s): Kwi Suk Kim: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Hyung Woo Lee: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Sun Joon Moon: Division of Endocrinology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic Of
    Hee Sim Han: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Eun Jeong Shin: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Jin Hee Baek: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Yoon Sook Cho: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Young Min Cho: Division of Endocrinology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic Of
  • Abstract:

    Background

    US">Dapagliflozin, a selective sodium-glucose co-transporter 2(SGLT2) inhibitor, lowers blood glucose by reducing glucose reabsorption at the proximal renal tubule in an insulin-independent manner.

    Purpose

    US">We aimed to evaluate the efficacy and safety of dapagliflozin and to identify the risk factors of adverse drug events in patients..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses